Clinical Trial: A Phase I Study to Evaluate the Safety, Tolerability, and Immunogenicity of an mRNA Vaccine Against Herpes Simplex Virus Type 2 (HSV-2) Post-Vaccination

U.S., Jan. 10 -- ClinicalTrials.gov registry received information related to the study (NCT07330440) titled 'A Phase I Study to Evaluate the Safety, Tolerability, and Immunogenicity of an mRNA Vaccine Against Herpes Simplex Virus Type 2 (HSV-2) Post-Vaccination' on Sept. 23, 2025.

Brief Summary: A Preliminary Evaluation of the Safety and Immunogenicity Post-Vaccination with Different Doses of an mRNA Vaccine against Herpes Simplex Virus Type 2 (HSV-2) in Populations with Different Serostatus

Study Start Date: Oct. 13, 2025

Study Type: INTERVENTIONAL

Condition: Genital Herpes

Intervention: BIOLOGICAL: Low-Dose Cohort

Each human dose is 0.25 mL

BIOLOGICAL: Mid-Dose Cohort

Each human dose is 0.5 mL

BIOLOGICAL: High-Dose Cohort

Each...